Advancing disease-curing therapeutics
On September 5, 2018 the University of California San Diego (UC San Diego) and Deerfield Management announced the creation of Poseidon Innovation, LLC to advance disease-curing therapeutics.
Through Deerfield’s $65-million commitment in Poseidon, UC San Diego investigators will have the funding and support to weather risky early-stage processes and expedite the drug-development cycle, allowing patients to receive treatment faster.
Projects that enter Poseidon will be directed by a joint steering committee and have access to sufficient funding for a full drug development program. Investigational New Drug (IND) application-enabling work will be done in labs on campus and externally.
As one of the top 15 research universities in the world, UC San Diego is driving innovation and change to advance society, propel economic growth and make our world a better place.
Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.
For more information, please visit www.deerfield.com.
What makes Poseidon unique?
Poseidon leverages UC San Diego’s courage to dissect convention, and together with Deerfield, creates cross-disciplinary, flexible approaches to advance research and break down silos that often cause roadblocks to advancement.
“Poseidon Innovation provides a new pathway for our investigators to push their discoveries to fruition. The funding and drug development support provided can enable therapies to get to patients faster. In breaking the traditional rules of discovery, we can create a greater impact and a better future for patients,” stated Sandra A. Brown, vice chancellor for research at UC San Diego.
Through Deerfield’s $65‐million commitment in Poseidon, UC San Diego investigators will have the funding and support to weather risky early‐stage processes and expedite the drug‐development cycle, allowing patients to receive treatment faster.